Table 2 Baseline lipid-lowering and anti-hypertensive medications
| Â | Rosiglitazone | Placebo | P value |
|---|---|---|---|
N (%) | (N = 27) | (N = 29) | Â |
Any such medication | 26 (96%) | 29 (100%) | Â |
Lipid-Lowering Medication | 21 (78%) | 24 (83%) | P = 0.89 |
Statin | 18 (67%) | 24 (83%) | Â |
Fibrate | 3 (11%) | 2 (7%) | Â |
Other lipid-lowering agents | 1 (4%) | 1 (3%) | Â |
Anti-Hypertensive Medication | 24 (89%) | 29 (100%) | P = 0.23 |
Diuretic | 13 (48%) | 10 (34%) | Â |
ACE inhibitor | 12 (44%) | 16 (55%) | Â |
Calcium channel antagonist | 11 (41%) | 19 (66%) | Â |
Beta-blocker | 9 (33%) | 14 (48%) | Â |
Alpha-blocker | 4 (15%) | 8 (28%) | Â |
Angiotensin 2 antagonist | 2 (7%) | 3 (10%) | Â |